Edward Gane
- Hepatology top 0.01%
- Hepatitis C virus research 320
- Liver Disease and Transplantation 54
- Hepatitis Viruses Studies and Epidemiology 25
- Epidemiology top 0.01%
- Hepatitis B Virus Studies 232
- Liver Disease Diagnosis and Treatment 210
- Transplantation top 0.5%
- Infectious Diseases top 0.5%
- HIV/AIDS drug development and treatment 63
- Immunology top 2%
-
- Systemic Lupus Erythematosus Research 33
-
- Organ Transplantation Techniques and Outcomes 23
- Co-authors
- John G. McHutchisonPatrick MarcellinGeorge LauYun‐Fan LiawTeerha PiratvisuthG. Mani SubramanianJia‐Horng KaoNikolai V. Naoumov
- Partner nations
- New ZealandUnited StatesUnited Kingdom
In The Last Decade
Edward Gane
436 papers receiving 21.1k citations
Hit Papers
Peers
Comparison fields: 5 of 131
- Hepatology 18.3k
- Epidemiology 17.8k
- Transplantation 599
- Infectious Diseases 2.7k
- Immunology 960
Countries citing papers authored by Edward Gane
This map shows the geographic impact of Edward Gane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Gane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Gane more than expected).
Fields of papers citing papers by Edward Gane
This network shows the impact of papers produced by Edward Gane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Gane. The network helps show where Edward Gane may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Edward Gane, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 1 | |
| 4 | Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.breakdown → | 2024 | 75 |
| 5 | 2023 | 4 | |
| 6 | 2023 | 0 | |
| 7 | 2023 | 20 | |
| 8 | 2022 | 17 | |
| 9 | 2022 | 4 | |
| 10 | 2021 | 30 | |
| 11 | 2020 | 3 | |
| 12 | 2020 | 1 | |
| 13 | 2020 | 60 | |
| 14 | 2019 | 9 | |
| 15 | 2016 | 22 | |
| 16 | 2014 | 23 | |
| 17 | 2014 | 8 | |
| 18 | 2010 | 354 | |
| 19 | 1997 | 86 | |
| 20 | 1996 | 30 |
About Edward Gane
Edward Gane is a scholar working on Hepatology, Epidemiology, Infectious Diseases, Transplantation and Genetics, having authored 454 papers that have together received 21.7k indexed citations. Recurring topics across this work include Hepatitis C virus research (320 papers), Hepatitis B Virus Studies (232 papers), Liver Disease Diagnosis and Treatment (210 papers), HIV/AIDS drug development and treatment (63 papers), Liver Disease and Transplantation (54 papers), Systemic Lupus Erythematosus Research (33 papers), Hepatitis Viruses Studies and Epidemiology (25 papers) and Organ Transplantation Techniques and Outcomes (23 papers). The work is most often cited by research in Hepatology (18.3k citations), Epidemiology (17.8k citations), Transplantation (599 citations), Infectious Diseases (2.7k citations) and Immunology (960 citations). Edward Gane has collaborated with scholars based in New Zealand, United States and United Kingdom. Frequent co-authors include John G. McHutchison, Patrick Marcellin, George Lau, Yun‐Fan Liaw, Teerha Piratvisuth, G. Mani Subramanian, Jia‐Horng Kao, Nikolai V. Naoumov, Stefan Zeuzem and E. Jenny Heathcote. Their work appears in journals such as Journal of Hepatology, Gastroenterology, Hepatology, Journal of Viral Hepatitis and Liver International.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.